St. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.
Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
Cells. 2022 Apr 8;11(8):1267. doi: 10.3390/cells11081267.
Ewing sarcoma (ES) is a rare aggressive cancer of bone and soft tissue that is mainly characterized by a reciprocal chromosomal translocation. As a result, about 90% of cases express the EWS-FLI1 fusion protein that has been shown to function as an aberrant transcription factor driving sarcomagenesis. ES is the second most common malignant bone tumor in children and young adults. Current treatment modalities include dose-intensified chemo- and radiotherapy, as well as surgery. Despite these strategies, patients who present with metastasis or relapse still have dismal prognosis, warranting a better understanding of treatment resistant-disease biology in order to generate better prognostic and therapeutic tools. Since the genomes of ES tumors are relatively quiet and stable, exploring the contributions of epigenetic mechanisms in the initiation and progression of the disease becomes inevitable. The search for novel biomarkers and potential therapeutic targets of cancer metastasis and chemotherapeutic drug resistance is increasingly focusing on long non-coding RNAs (lncRNAs). Recent advances in genome analysis by high throughput sequencing have immensely expanded and advanced our knowledge of lncRNAs. They are non-protein coding RNA species with multiple biological functions that have been shown to be dysregulated in many diseases and are emerging as crucial players in cancer development. Understanding the various roles of lncRNAs in tumorigenesis and metastasis would determine eclectic avenues to establish therapeutic and diagnostic targets. In ES, some lncRNAs have been implicated in cell proliferation, migration and invasion, features that make them suitable as relevant biomarkers and therapeutic targets. In this review, we comprehensively discuss known lncRNAs implicated in ES that could serve as potential biomarkers and therapeutic targets of the disease. Though some current reviews have discussed non-coding RNAs in ES, to our knowledge, this is the first review focusing exclusively on ES-associated lncRNAs.
尤因肉瘤(ES)是一种罕见的侵袭性骨和软组织恶性肿瘤,主要特征是染色体的相互易位。因此,大约 90%的病例表达 EWS-FLI1 融合蛋白,该蛋白已被证明作为异常转录因子驱动肉瘤发生。ES 是儿童和青少年中第二常见的恶性骨肿瘤。目前的治疗方法包括剂量强化化疗和放疗以及手术。尽管采用了这些策略,但出现转移或复发的患者预后仍然较差,因此需要更好地了解耐药性疾病的生物学机制,以生成更好的预后和治疗工具。由于 ES 肿瘤的基因组相对安静且稳定,因此探索表观遗传机制在疾病发生和进展中的作用是不可避免的。寻找癌症转移和化疗耐药性的新型生物标志物和潜在治疗靶点,越来越多地集中在长非编码 RNA(lncRNA)上。高通量测序的基因组分析的最新进展极大地扩展和推进了我们对 lncRNA 的认识。它们是具有多种生物学功能的非蛋白编码 RNA 种类,已被证明在许多疾病中失调,并且正在成为癌症发展的关键参与者。了解 lncRNA 在肿瘤发生和转移中的各种作用将确定建立治疗和诊断靶点的多种途径。在 ES 中,一些 lncRNA 已被证明与细胞增殖、迁移和侵袭有关,这些特征使它们成为相关的生物标志物和治疗靶点。在这篇综述中,我们全面讨论了已知与 ES 相关的 lncRNA,它们可能成为该疾病的潜在生物标志物和治疗靶点。尽管目前有一些综述讨论了 ES 中的非编码 RNA,但据我们所知,这是第一篇专门关注 ES 相关 lncRNA 的综述。